Gilead, Galapagos: Filgotinib 200mg Achieved Primary Endpoints in Phase 2b/3 Trial
May 20 2020 - 05:08PM
Dow Jones News
By Stephen Nakrosis
Gilead Sciences Inc. and Galapagos NV on Wednesday said results
from a trial of their filgotinib 200 mg in adult patients with
moderately to severely active ulcerative colitis showed it had
"achieved all primary endpoints in the study, inducing clinical
remission at Week 10 and maintaining clinical remission at Week 58
in a significantly higher proportion of patients compared with
placebo."
The companies said the Phase 2b/3 Selection trial evaluated "the
efficacy and safety of the investigational, oral, once-daily,
selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or
biologic-experienced adult patients with moderately to severely
active ulcerative colitis."
The companies also said filgotinib 100 mg didn't achieve
statistically significant clinical remission at Week 10.
Detailed results from the trial will be submitted for
presentation at a future scientific conference, the companies
said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 20, 2020 16:53 ET (20:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2023 to Mar 2024